Bcise a Bust

[anonymous]

What a farce. Selling this AI 3 years late.
Exenatide always suffered from bad sales and marketing. Bcise is going nowhere it’s the same jack offs who use some of the pen. Means no new trxs to the Bydureon family.

 

[anonymous]

Don’t blame failure on exenatide, the molecule. Exenatide is an excellent molecule, but poorly managed, executed and delivered by mediocre AZ management and its Diabetes salesforce. Bcise is nothing more than a Trulicity copycat. Yes, the barrel is no better and the reps suck, both ESS and PSS. Farxiga will save you, NOT!

 

[anonymous]

Don’t blame failure on exenatide, the molecule. Exenatide is an excellent molecule, but poorly managed, executed and delivered by mediocre AZ management and its Diabetes salesforce. Bcise is nothing more than a Trulicity copycat. Yes, the barrel is no better and the reps suck, both ESS and PSS. Farxiga will save you, NOT!

Same jack offs rotating through leadership positions. No mystery there.

 

[anonymous]

its hard sell against those with cardio benefit. Apparently GI s/e not that different in clinical practice.

 

[anonymous]

its hard sell against those with cardio benefit. Apparently GI s/e not that different in clinical practice.

Bydureon has no cardio benefit; Victoza does. Farxiga has no cardio benefit; Jardiance does. Type 2 diabetes patients are all high risk for cardiovascular complications. If you were a good doctor, and not an AZ $peaker, which of the glp1 or sglt2 drugs would you give your patient?

 

[anonymous]

Bydureon has no cardio benefit; Victoza does. Farxiga has no cardio benefit; Jardiance does. Type 2 diabetes patients are all high risk for cardiovascular complications. If you were a good doctor, and not an AZ $peaker, which of the glp1 or sglt2 drugs would you give your patient?

victoza got the cv nod by the narrowest of margins. the same margin of difference byd didn't. jardiance is for 2nd and look at the pt pop. that tilted the scales. Far is going after primary prevent. All HCPs see it all as class effect. Plus, victoza is dead. Ozemp, with its retinop. and headache of a titration regimen is NOT the answer.

 

[anonymous]

victoza got the cv nod by the narrowest of margins. the same margin of difference byd didn't. jardiance is for 2nd and look at the pt pop. that tilted the scales. Far is going after primary prevent. All HCPs see it all as class effect. Plus, victoza is dead. Ozemp, with its retinop. and headache of a titration regimen is NOT the answer.

I hope AZ will defend you just as much as you’re defending AZ. When the time comes, they won’t even know your name. What dirt do they have on you that made you so defensive of their mediocre diabetes products?

 

[anonymous]

hi sarah!

 

[anonymous]

Bcise is not where the company needs it to be. No surprise.
When do the cuts start? ESS should be first to go.

 

[anonymous]

victoza got the cv nod by the narrowest of margins. the same margin of difference byd didn't. jardiance is for 2nd and look at the pt pop. that tilted the scales. Far is going after primary prevent. All HCPs see it all as class effect. Plus, victoza is dead. Ozemp, with its retinop. and headache of a titration regimen is NOT the answer.

Class effect? If efficacy is a class effect so is safety! Count your toes!

 

[anonymous]

Bcise is not where the company needs it to be. No surprise.
When do the cuts start? ESS should be first to go.

Not this again; ESS vs. Diabetes Primary Care. Really?

 

[anonymous]

Not this again; ESS vs. Diabetes Primary Care. Really?

Right on. No need for rep on rep hate.
Just saying though, can’t see BCise doing anything in the future.
Just holdin out for declare data.
Farxiga is only chance for all PSS and ESS to keep jobs.
We’re SOL without declare comin thru.

 

[anonymous]

This company is reactive in every way. They have no clue how to market a product in this space. It’s time they bring in someone at the top who knows what they are doing. Other companies use whatever clinical data they have to sell. AZ handicaps it’s sales force and the numbers reflect that.

 

[anonymous]

So let's be honest here and understand the mindset of our customer. The harsh reality is Bydureon had been building its' negative product profile over the past 12 yrs. In the meantime other companies with much more user-friendly , simple
devices have become available, with much more effective and skilled marketing strategies. B-Cise is too late to the party!!! If we offered an advantage over competition we might have a chance, but all we can hope for is getting the "scraps." Our inability to reach company objectives is not OUR fault!!!

 

[anonymous]

Time for Intarcia ! This disruptive unicorn throws the new drug paradigm out the window with a once a year pump. Led by the world’s greatest marketer, k Graves, a former AZ’er. Kurt is t a leader that only knows how to win. So throw off those loser comments and strap on Intarcia. That is if you have the courage to trAnsform diabetes ! We re #1 with the once a year pump that means you’ll never forget your meds again. Say goodbye to sleepless nights wondering “did I forget to take my exenatide ?” Sleep like a baby knowing your pump is there working for you !, Intarcia proudly disrupting the story that you can only get better with a new drug.....No Longer ! Once a year, better efficacy that Byetta or Bydureon ,,find the leadership that can make your sales numbers him... INTARCIA!

 

[anonymous]

So right most AZ sampledroppers couldn't make it in a surgical/capital equipment world. Big bucks aren't made for little fucks